In vitro studies have revealed that, in both murine and human BC and PC cells, endowed with IL-6Rα and gp130, IL-30 treatment not only stimulates proliferation, but also activates a cancer progression program, including the production of myeloid cell proliferation and chemotactic factors [16,81], such as colony stimulating factor 1, CSF1 [82], chemokine C-X-C motif ligand 1 and 2, CXCL1, CXCL2 [83], IL-1β, IL-8 [84], and IL-6 [85]. Here, IL27 is linked to cancer.